<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5142C7EB-72D4-48F8-B2B0-9445D455C760"><gtr:id>5142C7EB-72D4-48F8-B2B0-9445D455C760</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>G</gtr:otherNames><gtr:surname>Gazzard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/10AE55C3-2E24-453C-914B-EF7D5C30D807"><gtr:id>10AE55C3-2E24-453C-914B-EF7D5C30D807</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Tang</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4022124B-F53A-438E-AAA6-F7C75C17CD04"><gtr:id>4022124B-F53A-438E-AAA6-F7C75C17CD04</gtr:id><gtr:firstName>Philippa</gtr:firstName><gtr:surname>Easterbrook</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3D1BE2EA-694D-41BA-8055-D1DB7D3D3658"><gtr:id>3D1BE2EA-694D-41BA-8055-D1DB7D3D3658</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Nicholas</gtr:otherNames><gtr:surname>Phillips</gtr:surname><gtr:orcidId>0000-0003-2384-4807</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8A2B4F6A-6F56-48D4-8A12-2187DF3414F7"><gtr:id>8A2B4F6A-6F56-48D4-8A12-2187DF3414F7</gtr:id><gtr:firstName>Valerie</gtr:firstName><gtr:surname>Delpech</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A6BAEC07-E057-4F0A-933A-BF3E851B5C99"><gtr:id>A6BAEC07-E057-4F0A-933A-BF3E851B5C99</gtr:id><gtr:firstName>Abdel</gtr:firstName><gtr:otherNames>Ghayoum</gtr:otherNames><gtr:surname>Babiker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A81EE031-ECD5-485B-A861-0885F2C2D5F0"><gtr:id>A81EE031-ECD5-485B-A861-0885F2C2D5F0</gtr:id><gtr:firstName>Chloe</gtr:firstName><gtr:surname>Orkin</gtr:surname><gtr:orcidId>0000-0001-6168-6745</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FEA48EF7-D13D-402E-BD13-A8E0D740166E"><gtr:id>FEA48EF7-D13D-402E-BD13-A8E0D740166E</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2B31CDFC-9A2D-42FB-8CF1-0FB122E4CDB3"><gtr:id>2B31CDFC-9A2D-42FB-8CF1-0FB122E4CDB3</gtr:id><gtr:firstName>Achim</gtr:firstName><gtr:surname>Schwenk</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/275BDF7A-7C42-40AE-A49E-FD1E2CD03215"><gtr:id>275BDF7A-7C42-40AE-A49E-FD1E2CD03215</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Sabin</gtr:surname><gtr:orcidId>0000-0001-5173-2760</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/626392FD-F63C-452E-B6B3-C5B85ED84586"><gtr:id>626392FD-F63C-452E-B6B3-C5B85ED84586</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Gilson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F3B01B68-39AA-44F3-96E2-DAB107BBE5E4"><gtr:id>F3B01B68-39AA-44F3-96E2-DAB107BBE5E4</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Goldberg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E4E1E0D9-BA6D-4007-8B53-AFB93A0F6772"><gtr:id>E4E1E0D9-BA6D-4007-8B53-AFB93A0F6772</gtr:id><gtr:firstName>Clifford</gtr:firstName><gtr:surname>Leen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/84E83045-C16C-48F2-AF16-F3E4032A80B4"><gtr:id>84E83045-C16C-48F2-AF16-F3E4032A80B4</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Fisher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3C4D0D08-B91B-46CF-AEBD-7CCAA43F89FC"><gtr:id>3C4D0D08-B91B-46CF-AEBD-7CCAA43F89FC</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Walsh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F4C48495-1923-4707-89F9-8E633268BD2A"><gtr:id>F4C48495-1923-4707-89F9-8E633268BD2A</gtr:id><gtr:firstName>Deenan</gtr:firstName><gtr:surname>Pillay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/664FA0A0-B6F5-431F-AA4E-4D5070BAD879"><gtr:id>664FA0A0-B6F5-431F-AA4E-4D5070BAD879</gtr:id><gtr:firstName>Kholoud</gtr:firstName><gtr:surname>Porter</gtr:surname><gtr:orcidId>0000-0002-9226-6206</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B389ADFC-6CD6-40BA-AD3F-29480E9B081B"><gtr:id>B389ADFC-6CD6-40BA-AD3F-29480E9B081B</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Anderson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/168CFD16-EA26-4A8A-B3E6-5E11BD817F3E"><gtr:id>168CFD16-EA26-4A8A-B3E6-5E11BD817F3E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Tyre</gtr:otherNames><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/249C2F81-B237-4176-8820-4C42F734EC0D"><gtr:id>249C2F81-B237-4176-8820-4C42F734EC0D</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Gompels</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600337"><gtr:id>D9EAA277-2809-41A1-8705-F6E8507D8B47</gtr:id><gtr:title>The uses and outcomes of treatment of HIV infection in the UK</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600337</gtr:grantReference><gtr:abstractText>Over the last ten years, the drugs used to treat HIV have improved dramatically, leading to huge reductions in the number of people dying from AIDS in the UK and in other developed countries. However, these drugs may have side effects, some of which may be life-threatening, which may make it difficult for a patient to take all of their tablets. Furthermore, patients who forget to take their tablets at the right time, or who take fewer tablets than they are supposed to, may develop HIV strains that don?t respond to these drugs, or to other drugs that they may receive in the future. Although there are a number of treatments that can be used if this happens, there is a worry that at some stage, patients may run out of treatment options and may once again start to become sick and die. As part of this application we will use a combination of data analysis and mathematical modelling to investigate the conditions in which this situation could arise. This will allow us to identify ways in which these treatments could be used more effectively, to minimise the risk of this happening.</gtr:abstractText><gtr:technicalSummary>The use of highly active antiretroviral therapy (HAART) has had a dramatic impact on the health of individuals infected with HIV. However, whilst the majority of individuals treated for the first time will experience good virological and immunological responses to therapy, the ultimate benefits of therapy are threatened by a number of factors, including the development of adverse effects of treatment, problems of maintaining the high levels of adherence required to sustain virological suppression and the development of resistant strains of HIV. It is not clear whether new drugs with improved toxicity profiles and reduced cross-resistance to other drugs will continue to be developed at a sufficient pace to ensure that all patients continue to have options available to them. We therefore hypothesise that the tremendous benefits of HAART will gradually be negated by a general exhaustion of treatment options precipitated by these factors.

We wish to use data from the UK Collaborative HIV Cohort Study and the UK Collaborative Group on HIV Drug Resistance to describe the immunological and virological outcomes on first-line, second-line and subsequent treatment regimens, to describe the frequency of development of drug mutations in patients starting HAART, to describe the virological responses to newly developed drugs in patients with multi-drug resistant HIV and to describe the rate of treatment-limiting toxicity of different antiretroviral drugs. These large databases were initiated in 2001 and are ideally placed to address these issues. The answers to these questions will then be incorporated into a novel mathematical model that has been developed to make predictions of outcomes of individuals with HIV infection until 2010. This model will allow us to assess the likelihood that treatment exhaustion will ultimately occur. By varying the parameter values in this model we will be able to investigate situations under which treatment exhaustion is more or less likely. Such projections will be important for understanding the urgency of the need for new drugs which are active against resistant strains of HIV and for planning of health care resources likely to be required in the future.</gtr:technicalSummary><gtr:fund><gtr:end>2009-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>745339</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>UK HIV Drug Resistance Database</gtr:description><gtr:id>68285AB0-5AA1-40F5-91F6-1250E2DDFAD5</gtr:id><gtr:impact>Publications as listed in section 2 and further grant funding (described above)</gtr:impact><gtr:outcomeId>6ACA6DA042E-1</gtr:outcomeId><gtr:partnerContribution>Through collaboration with this study we have successfully applied for a new five-year programme grant from the MRC (G0900274)</gtr:partnerContribution><gtr:piContribution>The studies have provided joint scientific leadership and have equally contributed to statistical analyses</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation of results to various groups of health-care professionals</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6C7127D0-7137-406B-9101-F75F567780A9</gtr:id><gtr:impact>Presented results from study at many clinical and scientific meetings in the UK and worldwide.

The study is now well known within the HIV research community in the UK and in Europe. Study outputs are frequently cited in national and international HIV treatment guidelines, as well as in community literature.</gtr:impact><gtr:outcomeId>AFC156A78FB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2225930</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E45093C4-C361-4B7D-8D7A-9F4F17D6BECE</gtr:id><gtr:outcomeId>CB6C756E16B0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1023240</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/Wellcome Trust/ESRC/EPSRC Joint initiative in Electronic Patient Records and Databases</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E344A61F-1C65-4BD4-A329-4C082B335D67</gtr:id><gtr:outcomeId>8DD619145380</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Inclusion in treatment guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>BF596808-DE18-49CA-A918-E2D153ADFF89</gtr:id><gtr:outcomeId>655CFEB9540</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Creation of study database.</gtr:description><gtr:id>A4D98FFB-0870-4ECC-ACC4-B26F4581030B</gtr:id><gtr:impact>Other researchers are encouraged to access the study database to perform their own analyses - this has let to many joint publications/presentations from the study.</gtr:impact><gtr:outcomeId>3BD68D8F764</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UK CHIC database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5B46AB4F-109C-453B-8B29-7160DFBC0988</gtr:id><gtr:title>Virological response to initial antiretroviral regimens containing abacavir or tenofovir.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>C3072DE40F1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ED293BC-C445-459D-8E2E-60D96E9F260A</gtr:id><gtr:title>Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8ddf4eb8bd657dafa0f77c1c74dd383"><gtr:id>c8ddf4eb8bd657dafa0f77c1c74dd383</gtr:id><gtr:otherNames>United Kingdom Collaborative HIV Cohort Study</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>02A2DC7C184</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99E950D4-ED1F-4261-B504-4F0A6B3450D2</gtr:id><gtr:title>Renal tubular disease in the era of combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d426d779c840a490da55f26dbb7b7238"><gtr:id>d426d779c840a490da55f26dbb7b7238</gtr:id><gtr:otherNames>Hamzah L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d990dd630825.33172556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A3FF33D-4C86-45DF-ACE8-84A0DB7B58C3</gtr:id><gtr:title>CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>E28917FB55E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1DAEFFB-63C6-445B-81FF-75E139AF3DEA</gtr:id><gtr:title>Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/440cbe8115805a4c83702556d9fc2e7c"><gtr:id>440cbe8115805a4c83702556d9fc2e7c</gtr:id><gtr:otherNames>Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>C872F2E4E6E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>796C4F1B-2D31-4287-B29B-8BEB56F91764</gtr:id><gtr:title>Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/801b89bcbbadfe35293e42012e24ca43"><gtr:id>801b89bcbbadfe35293e42012e24ca43</gtr:id><gtr:otherNames>Barber TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>doi_55faa1aa1ee1b372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C659EC0-C437-4074-99BD-1C0C923297AA</gtr:id><gtr:title>Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f57a80aa717e9c41b112e507dcd8ea74"><gtr:id>f57a80aa717e9c41b112e507dcd8ea74</gtr:id><gtr:otherNames>Gompels M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12455_25_22279171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C84DF7D5-13F9-4FDF-B99C-89FA8F1A3299</gtr:id><gtr:title>A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/282ae484e5c075253c677437743d1964"><gtr:id>282ae484e5c075253c677437743d1964</gtr:id><gtr:otherNames>Patterson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5a2fd73d3f69c2.32890936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62EFB51D-0706-4809-A818-5CDFF0C5754A</gtr:id><gtr:title>The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1704e865bab1ab31ac7ca16fbc2f65a4"><gtr:id>1704e865bab1ab31ac7ca16fbc2f65a4</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>08DDAF73147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F830FB5-37AC-4379-A555-3E411F154D5E</gtr:id><gtr:title>Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>54622bc3130425.57864261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C08AC72D-A13A-4946-80E0-721EE5A0B533</gtr:id><gtr:title>Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d990ddb469e1.86372148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5703035-6C88-40D6-9DDD-702F6A9CDA3D</gtr:id><gtr:title>Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/154626858cc42f66f33a93cb72762480"><gtr:id>154626858cc42f66f33a93cb72762480</gtr:id><gtr:otherNames>Garvey L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>546229db4ae482.79853639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD436911-52D2-49F4-B446-EF762AEF18E3</gtr:id><gtr:title>HLA B*5701 status, disease progression, and response to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dbd487b9375405800430d15de0afeed"><gtr:id>9dbd487b9375405800430d15de0afeed</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort Study Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55f983983d948d36</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E124B4CD-334B-4EEA-BF1D-5A019CD836E6</gtr:id><gtr:title>Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f78916ca445ce7ca828997daa4a8303"><gtr:id>0f78916ca445ce7ca828997daa4a8303</gtr:id><gtr:otherNames>Huntington SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55f983983db2651a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC352BA7-A8D3-4FE0-B253-53C9B47C738E</gtr:id><gtr:title>End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3110d40d6f2e49b9e9f39f461ad254c0"><gtr:id>3110d40d6f2e49b9e9f39f461ad254c0</gtr:id><gtr:otherNames>Gathogo E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>54610243a61f76.59250460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F28036D-DC95-45FB-9FD3-A01DF2021D93</gtr:id><gtr:title>Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b18ef1bb71f9d1c5b2422991e2bebc17"><gtr:id>b18ef1bb71f9d1c5b2422991e2bebc17</gtr:id><gtr:otherNames>Hughes RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>546229dc3ba775.17076822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2459F582-C474-4C0B-9EE3-A80797C7BA2A</gtr:id><gtr:title>Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d90882e650eb8a23e2bf5788035224d2"><gtr:id>d90882e650eb8a23e2bf5788035224d2</gtr:id><gtr:otherNames>Benzie AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>E017BA96FE4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53AD0B49-0682-4627-BAA1-C75A9C99D413</gtr:id><gtr:title>Aspartate aminotransferase-to-platelet ratio index is a powerful predictor of mortality among HIV-positive patients.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e65fa8c83ae955be691251a1f8d9da9"><gtr:id>9e65fa8c83ae955be691251a1f8d9da9</gtr:id><gtr:otherNames>Post FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12455_25_23107784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E74E224-FC28-40E0-9876-E9AEE564A55E</gtr:id><gtr:title>Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients.</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c49755f7f5b167b37c218aa065bc555"><gtr:id>5c49755f7f5b167b37c218aa065bc555</gtr:id><gtr:otherNames>Ibrahim F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>pm_12455_25_22521282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97931151-6AF8-4B49-BDDF-0275929F9D81</gtr:id><gtr:title>Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60e563cdcf9df64aa0ffb7a1afb09595"><gtr:id>60e563cdcf9df64aa0ffb7a1afb09595</gtr:id><gtr:otherNames>Huntington S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55faa1aa1eeab4c3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9E353C5-D3DB-449D-8A5E-96F120C3492D</gtr:id><gtr:title>Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f9f2f726c29e3ec6d0a6d004eec899b"><gtr:id>0f9f2f726c29e3ec6d0a6d004eec899b</gtr:id><gtr:otherNames>Porter K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>879E0593B3A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>109F2640-F0A2-4BEC-8960-682E3E7D5502</gtr:id><gtr:title>Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/619570981e5c1fd56fbbfd0fa3f49528"><gtr:id>619570981e5c1fd56fbbfd0fa3f49528</gtr:id><gtr:otherNames>Dunn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>1E62F7CF7DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F1FBB4F-BAF9-4135-9E07-BCD1057688B3</gtr:id><gtr:title>Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5462271c2863f7.14698408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70162762-5DEB-405D-9C06-7AEE7B515E8E</gtr:id><gtr:title>The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68a3b528ff9b1f0d0bddbdf896177d53"><gtr:id>68a3b528ff9b1f0d0bddbdf896177d53</gtr:id><gtr:otherNames>Green H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>05ED626BBBC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCE6ADBB-C506-430D-8E89-F4A7C3A1E534</gtr:id><gtr:title>Clinical epidemiology of HIV-associated end-stage renal failure in the UK.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54623e78ad9885.07371630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>187C5E04-59DA-4E5D-A5B5-842ED7E51EE3</gtr:id><gtr:title>HIV diagnosis at CD4 count above 500 Cells/mm(3) and progression to below 350 Cells/mm(3) without Antiretroviral therapy</gtr:title><gtr:parentPublicationTitle>JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd35787cdf0b91e7593902cfa818ce92"><gtr:id>dd35787cdf0b91e7593902cfa818ce92</gtr:id><gtr:otherNames>Phillips Andrew N.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5a36030209cb21.18113185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E0D2A1B-E5B5-426A-ADEA-D4FE130D9858</gtr:id><gtr:title>Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/801b89bcbbadfe35293e42012e24ca43"><gtr:id>801b89bcbbadfe35293e42012e24ca43</gtr:id><gtr:otherNames>Barber TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>546229dc17a177.82964105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D36EDE40-AEE1-44DE-AC20-85F913403368</gtr:id><gtr:title>Uptake and outcome of combination antiretroviral therapy in men who have sex with men according to ethnic group: the UK CHIC Study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ce5d2de4f761592c4eb83580daf4c87"><gtr:id>6ce5d2de4f761592c4eb83580daf4c87</gtr:id><gtr:otherNames>United Kingdom Collaborative HIV Cohort Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_12455_25_22205437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD908542-91DA-4B83-ACEE-C448C616608F</gtr:id><gtr:title>Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57c30723062483d637e0ebc9fff97497"><gtr:id>57c30723062483d637e0ebc9fff97497</gtr:id><gtr:otherNames>Waters L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>54622bc2bd8d74.32230172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9C9DBE6-167C-42DF-8360-BA93C67388F7</gtr:id><gtr:title>Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2bb0b05db50d7622ad34646ff7bfe15"><gtr:id>a2bb0b05db50d7622ad34646ff7bfe15</gtr:id><gtr:otherNames>Easterbrook PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>C70A520B014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>390DB513-14D1-4B70-92D5-6D73FCDC3334</gtr:id><gtr:title>The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afdf783165c02c37a71e5e1baef67b12"><gtr:id>afdf783165c02c37a71e5e1baef67b12</gtr:id><gtr:otherNames>Turner J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>F038C95BB65</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90CB9FDA-EFDD-4F7F-96DE-6AAE05FA189C</gtr:id><gtr:title>The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60e563cdcf9df64aa0ffb7a1afb09595"><gtr:id>60e563cdcf9df64aa0ffb7a1afb09595</gtr:id><gtr:otherNames>Huntington S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d990dc99ea88.69954376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9A567FA-ADEB-4552-B75A-8CD1AA0C7C77</gtr:id><gtr:title>The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>9A3E58C38D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6DFC508-3A52-4521-A37D-D16DB2A808FD</gtr:id><gtr:title>Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c2dc3cb91c8d7e7089e83ba9820a2f"><gtr:id>03c2dc3cb91c8d7e7089e83ba9820a2f</gtr:id><gtr:otherNames>Bansi LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>BB6601383D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8169DD33-4F8F-4ABE-AD08-93E6076F8E8C</gtr:id><gtr:title>Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a35586be0a5b78e8a4231529ab32ca2"><gtr:id>1a35586be0a5b78e8a4231529ab32ca2</gtr:id><gtr:otherNames>O'Connor JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>546227522db689.11789330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3D0E770-0A08-4933-A3AF-16F59453BA9E</gtr:id><gtr:title>Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85a60e5066ab5ec74048e84f9e035c69"><gtr:id>85a60e5066ab5ec74048e84f9e035c69</gtr:id><gtr:otherNames>Grant AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>C8DFE4EB7B2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3AF3FCD-E344-42CF-943E-FF8BBE676AA4</gtr:id><gtr:title>Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>54610389059a55.29660583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>931F4B47-7978-4E8D-B149-38382C2B27B2</gtr:id><gtr:title>REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care</gtr:title><gtr:parentPublicationTitle>Health Services and Delivery Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81faae467a1abeb3ea8a472699228491"><gtr:id>81faae467a1abeb3ea8a472699228491</gtr:id><gtr:otherNames>Howarth A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a2fd73038af05.52257640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD02FDCB-4215-46B7-A174-AD15C2D688BF</gtr:id><gtr:title>The impact of HIV drug resistance testing on changes to treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>546229db740234.61101242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B6F6124-0E04-4CD7-AA30-0E3BBD1237E3</gtr:id><gtr:title>Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>585d559b450019.24417085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C87B8869-02FB-49CC-B38B-9E25863D4C73</gtr:id><gtr:title>Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/512deaabd7076c84d8d971e1b9308875"><gtr:id>512deaabd7076c84d8d971e1b9308875</gtr:id><gtr:otherNames>Kesselring AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>3CF0D0FD051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F2526C5-EE9F-477B-AAC5-3CFE13A6B95D</gtr:id><gtr:title>Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46286eef88a09fac06d9580bfa9a952e"><gtr:id>46286eef88a09fac06d9580bfa9a952e</gtr:id><gtr:otherNames>Gilson RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>54623e788684f7.39008132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60E427E3-82DF-4205-A0F2-57B600AF0590</gtr:id><gtr:title>Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>C1229C641EF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B62EA23-7166-4DC8-BD5B-13FCCDDBED5D</gtr:id><gtr:title>The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e92b49e0e6e3d90f1828b5299dbf67bd"><gtr:id>e92b49e0e6e3d90f1828b5299dbf67bd</gtr:id><gtr:otherNames>Samuel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5462275276d9b1.39601372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>994237FA-DB7D-4F92-95AC-B667970E04EA</gtr:id><gtr:title>Predicting virological decay in patients starting combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d0ae6e7a98bbd0f130691f9c6ce1e21"><gtr:id>5d0ae6e7a98bbd0f130691f9c6ce1e21</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (UK CHIC) Writing Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>585d65df4b1b92.70089223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BF0A370-015E-49D9-8EA9-CBC4833E1368</gtr:id><gtr:title>Biomarkers to monitor safety in people on art and risk of mortality.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_12455_25_22330610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4ACA95D-33F0-47F4-BF5D-A41444492142</gtr:id><gtr:title>Is 1 alanine transaminase &amp;gt;200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>08DD5AE7C76</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A11B283E-1E5C-4F42-83F0-51ECA8F6BCE8</gtr:id><gtr:title>Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f78916ca445ce7ca828997daa4a8303"><gtr:id>0f78916ca445ce7ca828997daa4a8303</gtr:id><gtr:otherNames>Huntington SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>pm_12455_25_22839414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5027A59-A947-414F-BA42-64C53DAFD728</gtr:id><gtr:title>Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom</gtr:title><gtr:parentPublicationTitle>AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71c6e0e4266b25f71757f1793eb22db"><gtr:id>f71c6e0e4266b25f71757f1793eb22db</gtr:id><gtr:otherNames>Burns Sheila</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a3605dcce18e3.45276645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1E1BB09-EB61-455E-BE6D-6574C5124503</gtr:id><gtr:title>Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f78916ca445ce7ca828997daa4a8303"><gtr:id>0f78916ca445ce7ca828997daa4a8303</gtr:id><gtr:otherNames>Huntington SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12455_25_22713479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4236CDC-A737-483A-8805-7BC2A6DADFB0</gtr:id><gtr:title>HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b0e0090ceccbbd7fd17b20da7528b7"><gtr:id>47b0e0090ceccbbd7fd17b20da7528b7</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (CHIC) Study Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>chmEmtpGCGc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BF98675-1AA0-4DB0-93E8-0BBEC53FB886</gtr:id><gtr:title>HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>19D210033F6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFEE2E08-1B39-4EE1-B752-6FDD0E1D57A7</gtr:id><gtr:title>Response to combination antiretroviral therapy: variation by age.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d93c3705563a63508cbc695a152a149"><gtr:id>0d93c3705563a63508cbc695a152a149</gtr:id><gtr:otherNames>Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>E73A18FC315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EC26B71-67D4-4488-819C-DD770DDA23FC</gtr:id><gtr:title>What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/702db0aeed63393b610817f5ce6d8df1"><gtr:id>702db0aeed63393b610817f5ce6d8df1</gtr:id><gtr:otherNames>Grover D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>D9D3CC4D10D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A86BCAF-D85A-43CC-B315-E11ECCCF6440</gtr:id><gtr:title>Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c49755f7f5b167b37c218aa065bc555"><gtr:id>5c49755f7f5b167b37c218aa065bc555</gtr:id><gtr:otherNames>Ibrahim F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>pm_12455_25_22121232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A6B6C5D-88C2-4DA7-BFCF-C2BD020D8F90</gtr:id><gtr:title>Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>D062D78B9E4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E1B000A-CF35-426D-95CA-C38972963AF1</gtr:id><gtr:title>The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b4f4f0e21733962eec60068490aaae8"><gtr:id>8b4f4f0e21733962eec60068490aaae8</gtr:id><gtr:otherNames>Sabin CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>ADF168661A5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39E0CD78-300D-4EA0-94EE-B44AAD3F586C</gtr:id><gtr:title>CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda3c874d6e33c2fafcfea247a9eedbe"><gtr:id>cda3c874d6e33c2fafcfea247a9eedbe</gtr:id><gtr:otherNames>Bower M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>8FC01880C23</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>146996E2-EEAB-4472-A801-CA80455842B5</gtr:id><gtr:title>Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c926053cd3c7f247fa364994945f7609"><gtr:id>c926053cd3c7f247fa364994945f7609</gtr:id><gtr:otherNames>Booth JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>56d990dc23b1a4.33863097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFE2A2F4-D263-4D76-84B1-408D0C69CF09</gtr:id><gtr:title>Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee525c2e3a0983da94ca3d109d1764b"><gtr:id>9ee525c2e3a0983da94ca3d109d1764b</gtr:id><gtr:otherNames>UK Collaborative Group on HIV Drug Resistance</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>2BF81647BCC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0082413C-4C0B-46BA-98B8-FADD34C90FE5</gtr:id><gtr:title>Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5462271c4d84b6.69221181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2A454CE-35FA-4628-8F7C-A101029991BE</gtr:id><gtr:title>Data linkage reduces loss to follow-up in an observational HIV cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/714c11cae3bdf9319cae1a059307588e"><gtr:id>714c11cae3bdf9319cae1a059307588e</gtr:id><gtr:otherNames>Hill T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>54622bc2e1bfc7.39160065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFA86E41-5189-484D-B11B-FEABC4BFACEF</gtr:id><gtr:title>Non-uptake of highly active antiretroviral therapy among patients with a CD4 count &amp;lt; 350 cells/?L in the UK.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64fa8c17b9aa548557c762139ce65be3"><gtr:id>64fa8c17b9aa548557c762139ce65be3</gtr:id><gtr:otherNames>Kober C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>546229dbc35314.21327268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71A31C66-57A0-498B-A7AD-7CA1684F562E</gtr:id><gtr:title>Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>8B4639625B1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13D79BD9-B5B1-4933-B596-925D4F0B36CC</gtr:id><gtr:title>HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b0e0090ceccbbd7fd17b20da7528b7"><gtr:id>47b0e0090ceccbbd7fd17b20da7528b7</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (CHIC) Study Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>AE2A54C252B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8F3FF63-4808-4E86-B397-9AD370076EAA</gtr:id><gtr:title>Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5462271c04f6a1.05749434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14303724-B191-43B2-9B79-EE178EED745D</gtr:id><gtr:title>Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART na&amp;iuml;ve women.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60e563cdcf9df64aa0ffb7a1afb09595"><gtr:id>60e563cdcf9df64aa0ffb7a1afb09595</gtr:id><gtr:otherNames>Huntington S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>doi_55f983983dea18b1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E54B6C30-35D3-432D-9912-0ABBA0C5A0C3</gtr:id><gtr:title>Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>546229dbe73c29.09820792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AA9837B-14C3-48B7-BCA1-5D143ADC28C7</gtr:id><gtr:title>Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76c7e7f6d167384202514d2509288582"><gtr:id>76c7e7f6d167384202514d2509288582</gtr:id><gtr:otherNames>Nebbia G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>F74F42BCE12</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90925677-3B94-40A4-8940-4435313D83C4</gtr:id><gtr:title>Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>doi_55f983983d8baac1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>228CAFD4-FCFD-4129-8B7B-BFB8759BB68C</gtr:id><gtr:title>Factors influencing lopinavir and atazanavir plasma concentration.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5031911640D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B979ABC-05F7-4CFA-B5D9-B18D832ABFFB</gtr:id><gtr:title>Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d4c2f57f6f7c6e7b09cbfa839e2119c"><gtr:id>1d4c2f57f6f7c6e7b09cbfa839e2119c</gtr:id><gtr:otherNames>Geretti AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>1C34F2A7FAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>285B3E84-366A-497B-A72F-A669543BF625</gtr:id><gtr:title>Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56d990ddd8def3.69683509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D7993E1-937E-4B2E-A6DC-182BD5F88EFD</gtr:id><gtr:title>Development and application of a new measure of engagement in out-patient HIV care.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/365192f3fdd9512e949582a17de15e1e"><gtr:id>365192f3fdd9512e949582a17de15e1e</gtr:id><gtr:otherNames>Howarth AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>585d39b4924c22.65699587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C737DBFF-A5C9-4F6E-9F12-43EB126BB757</gtr:id><gtr:title>Late diagnosis in the HAART era: proposed common definitions and associations with mortality.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f61577ce5353e21eebcd751fd76540c9"><gtr:id>f61577ce5353e21eebcd751fd76540c9</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (UK CHIC) Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>CrywWzC5wPU</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600337</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>